VTV celebrates a double positive
Yesterday’s clinical study success has underlined VTV's status as a small-cap bet on Alzheibetes.
Cymabay is out, but for Genfit the band plays on
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
VTV’s diabetes reinvention gains some ground
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
